secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-06-03T20:02:22+00:00
Accession:  0001193125-26-255396
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon shareholders approve 2026 equity plan, elect directors at annual meeting
------------------------------------------------------------------------------

- Shareholders approved the 2026 Equity Incentive Plan: 58.6M for, 27.6M against, 842K abstain.
- New plan authorizes 4.4M new shares plus up to 14.72M shares from the prior plan (subject to expiry/forfeiture).
- All 8 director nominees elected; say-on-pay approved (82.2M for, 4.8M against), with 1-year frequency chosen.
- PricewaterhouseCoopers reappointed as auditor (90.4M for, 27.7K withheld); auditor remuneration authority approved.
- Voter turnout: 90.4M shares (93.54% of eligible) were represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526255396/0001193125-26-255396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526255396/xene-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-255396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer